双歧杆菌活菌联合蒙脱石散治疗小儿腹泻的疗效评价

Evaluation on Curative Effect of Bifidobacterium Viable Combined with Smectite Powder in Treatment of Infantile Diarrhea

目的讨论双歧杆菌活菌联合蒙脱石散治疗小儿腹泻的临床效果。方法选取该院救治的腹泻患儿120例,均选自2015年6月—2016年6月期间,所有患儿均实行基础的医治,根据自愿的原则分为实行蒙脱石散医治的对照组(n=60)和实行双歧杆菌活菌联合蒙脱石散医治的实验组(n=60)。在两组患儿实行医治3 d后,将两组患儿的医治的效果和患儿经过检验的各项免疫的指标的情况以及患儿的不良反应的情况实行比较。结果实验组的患儿的医治的总有效率(96.00%)大于对照组(83.33%),差异无统计学意义(P>0.05)。其中免疫指标lg G实验组医治后的量(16.03±0.71)g/L优于对照组(11.36±0.62)g/L,差异有统计学意义(P<0.05)。实验组的不良反应发生率(3.33%)和对照组的不良反应发生率(5.00%)相比,差异无统计学意义(P>0.05)。结论对于小儿腹泻的医治使用双歧杆菌活菌联合蒙脱石散可以有效提高医治的效果,增强患儿的免疫力,促进患儿恢复健康,具有重要的临床意义。

Objective To discuss the clinical effect of bifidobacterium viable combined with smectite powder in treatment of infantile di-arrhea. Methods 120 cases of children with diarrhea in our hospital from June 2015 to June 2016 were selected and divided into two groups with 60 cases in each, after 3d treatment, the treatment effect, various immune indicators after test and adverse reactions of children of the control group and the experimental group were compared. Results The total treatment effective rate in the experimental group was higher than that in the control group（95.00% vs 83.33%）, and the difference had no statistical significance（P〉0.05）, and the immune index Ig G amount after treatment in the experimental group was better than that in the control group [（16.03±0.71）g/L vs（11.36±0.62）g/L], and the difference had statistical significance（P〉0.05）, and the difference in the incidence rate of adverse reactions between the experimental group and the control group had no statistical significance（3.33% vs 5.005%）（P〉0.05）. Conclusion Bifidobacterium viable combined with smectite powder in treatment of infantile diarrhea can effectively improve the medical effect, en-hance the immunity of children and promote the children to recover, and it is of important clinical significance.